1
|
Jones RL, Wan Ahmad WAN, Woodward DF, Wang J. Nature of the slow relaxation of smooth muscle induced by a EP2 receptor agonist with a non-prostanoid structure. Prostaglandins Leukot Essent Fatty Acids 2013; 88:321-30. [PMID: 23419768 DOI: 10.1016/j.plefa.2013.01.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2012] [Revised: 01/19/2013] [Accepted: 01/22/2013] [Indexed: 10/27/2022]
Abstract
The remarkably slow onset/offset of relaxation of guinea-pig isolated trachea induced by a 'non-prostanoid' EP2 receptor agonist, (o-(o-benzyloxy)-cinnamyl)-cinnamic acid (coded (L)-9), was investigated. (L)-9 kinetics was slightly faster on mouse trachea and considerably faster on rabbit vena cava. In each case, reversal of (L)-9 relaxation by the selective EP2 antagonist ACA-23 was rapid and similar to other EP2 agonists (e.g. ONO-AE1-259). On guinea-pig aorta, in the presence of extensive EP2 receptor blockade, (L)-9 inhibited TP agonist-induced contraction more slowly than TP antagonists of similar affinity. The slower kinetics of (L)-9 appear to correlate with greater adventitial/submucosal barriers and thicker smooth muscle layers in the tissues examined. It is proposed that interactions of (L)-9 with EP2 and TP receptors are not rate-limiting, rather diffusion to and from the centre of the muscle mass is retarded by the high lipophilicity of (L)-9 (logP=6.69; ONO-AE1-259=3.95).
Collapse
Affiliation(s)
- Robert L Jones
- Cardiovascular Research Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK.
| | | | | | | |
Collapse
|
2
|
|
3
|
Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011; 63:471-538. [PMID: 21752876 DOI: 10.1124/pr.110.003517] [Citation(s) in RCA: 321] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
It is now more than 15 years since the molecular structures of the major prostanoid receptors were elucidated. Since then, substantial progress has been achieved with respect to distribution and function, signal transduction mechanisms, and the design of agonists and antagonists (http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=58). This review systematically details these advances. More recent developments in prostanoid receptor research are included. The DP(2) receptor, also termed CRTH2, has little structural resemblance to DP(1) and other receptors described in the original prostanoid receptor classification. DP(2) receptors are more closely related to chemoattractant receptors. Prostanoid receptors have also been found to heterodimerize with other prostanoid receptor subtypes and nonprostanoids. This may extend signal transduction pathways and create new ligand recognition sites: prostacyclin/thromboxane A(2) heterodimeric receptors for 8-epi-prostaglandin E(2), wild-type/alternative (alt4) heterodimers for the prostaglandin FP receptor for bimatoprost and the prostamides. It is anticipated that the 15 years of research progress described herein will lead to novel therapeutic entities.
Collapse
Affiliation(s)
- D F Woodward
- Dept. of Biological Sciences RD3-2B, Allergan, Inc., 2525 Dupont Dr., Irvine, CA 92612, USA.
| | | | | |
Collapse
|
4
|
Jones RL, Woodward DF, Wang JW, Clark RL. Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations. Br J Pharmacol 2011; 162:863-79. [PMID: 20973775 PMCID: PMC3042197 DOI: 10.1111/j.1476-5381.2010.01087.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2010] [Revised: 08/24/2010] [Accepted: 10/04/2010] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND AND PURPOSE The highly lipophilic acyl-sulphonamides L-798106 and L-826266 showed surprisingly slow antagonism of the prostanoid EP₃ receptor system in guinea-pig aorta. Roles of affinity and lipophilicity in the onset kinetics of these and other prostanoid ligands were investigated. EXPERIMENTAL APPROACH Antagonist selectivity was assessed using a panel of human recombinant prostanoid receptor-fluorimetric imaging plate reader assays. Potencies/affinities and onset half-times of agonists and antagonists were obtained on guinea-pig-isolated aorta and vas deferens. n-Octanol-water partition coefficients were predicted. KEY RESULTS L-798106, L-826266 and the less lipophilic congener (DG)-3ap appear to behave as selective, competitive-reversible EP₃ antagonists. For ligands of low to moderate lipophilicity, potency increments for EP₃ and TP (thromboxane-like) agonism on guinea-pig aorta (above pEC₅₀ of 8.0) were associated with progressively longer onset half-times; similar trends were found for TP and histamine H₁ antagonism above a pA₂ limit of 8.0. In contrast, L-798106 (EP₃), L-826266 (EP₃, TP) and the lipophilic H₁ antagonists astemizole and terfenadine exhibited very slow onset rates despite their moderate affinities; (DG)-3ap (EP₃) had a faster onset. Agonism and antagonism on the vas deferens EP₃ system were overall much faster, although trends were similar. CONCLUSIONS AND IMPLICATIONS High affinity and high liphophilicity may contribute to the slow onsets of prostanoid ligands in some isolated smooth muscle preparations. Both relationships are explicable by tissue disposition under the limited diffusion model. EP₃ antagonists used as research tools should have moderate lipophilicity. The influence of lipophilicity on the potential clinical use of EP₃ antagonists is discussed.
Collapse
MESH Headings
- Acrylamides/chemistry
- Acrylamides/metabolism
- Acrylamides/pharmacology
- Animals
- Aorta, Thoracic/metabolism
- Guinea Pigs
- HEK293 Cells
- Humans
- Hydrophobic and Hydrophilic Interactions
- In Vitro Techniques
- Isoenzymes/antagonists & inhibitors
- Isoenzymes/genetics
- Isoenzymes/metabolism
- Kinetics
- Ligands
- Male
- Models, Biological
- Muscle Contraction/drug effects
- Muscle Relaxation/drug effects
- Muscle, Smooth/drug effects
- Muscle, Smooth/metabolism
- Naphthalenes/chemistry
- Naphthalenes/metabolism
- Naphthalenes/pharmacology
- Neuromuscular Agents/chemistry
- Neuromuscular Agents/metabolism
- Neuromuscular Agents/pharmacology
- Receptors, Eicosanoid/agonists
- Receptors, Eicosanoid/antagonists & inhibitors
- Receptors, Eicosanoid/genetics
- Receptors, Eicosanoid/metabolism
- Receptors, Prostaglandin E, EP3 Subtype/agonists
- Receptors, Prostaglandin E, EP3 Subtype/antagonists & inhibitors
- Receptors, Prostaglandin E, EP3 Subtype/genetics
- Receptors, Prostaglandin E, EP3 Subtype/metabolism
- Recombinant Proteins/agonists
- Recombinant Proteins/antagonists & inhibitors
- Recombinant Proteins/metabolism
- Sulfonamides/metabolism
- Sulfonamides/pharmacology
- Vas Deferens/metabolism
Collapse
Affiliation(s)
- R L Jones
- Cardiovascular Research Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
| | | | | | | |
Collapse
|
5
|
Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 2009; 158:104-45. [PMID: 19624532 PMCID: PMC2795261 DOI: 10.1111/j.1476-5381.2009.00317.x] [Citation(s) in RCA: 128] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2009] [Accepted: 04/07/2009] [Indexed: 01/17/2023] Open
Abstract
Identification of the primary products of cyclo-oxygenase (COX)/prostaglandin synthase(s), which occurred between 1958 and 1976, was followed by a classification system for prostanoid receptors (DP, EP(1), EP(2) ...) based mainly on the pharmacological actions of natural and synthetic agonists and a few antagonists. The design of potent selective antagonists was rapid for certain prostanoid receptors (EP(1), TP), slow for others (FP, IP) and has yet to be achieved in certain cases (EP(2)). While some antagonists are structurally related to the natural agonist, most recent compounds are 'non-prostanoid' (often acyl-sulphonamides) and have emerged from high-throughput screening of compound libraries, made possible by the development of (functional) assays involving single recombinant prostanoid receptors. Selective antagonists have been crucial to defining the roles of PGD(2) (acting on DP(1) and DP(2) receptors) and PGE(2) (on EP(1) and EP(4) receptors) in various inflammatory conditions; there are clear opportunities for therapeutic intervention. The vast endeavour on TP (thromboxane) antagonists is considered in relation to their limited pharmaceutical success in the cardiovascular area. Correspondingly, the clinical utility of IP (prostacyclin) antagonists is assessed in relation to the cloud hanging over the long-term safety of selective COX-2 inhibitors. Aspirin apart, COX inhibitors broadly suppress all prostanoid pathways, while high selectivity has been a major goal in receptor antagonist development; more targeted therapy may require an intermediate position with defined antagonist selectivity profiles. This review is intended to provide overviews of each antagonist class (including prostamide antagonists), covering major development strategies and current and potential clinical usage.
Collapse
Affiliation(s)
- R L Jones
- Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK.
| | | | | |
Collapse
|
6
|
Chen J, Woodward DF, Coleman RA, Jones RL, Lydford SJ. Prostanoid receptor assays. CURRENT PROTOCOLS IN PHARMACOLOGY 2001; Chapter 4:Unit4.18. [PMID: 21959759 DOI: 10.1002/0471141755.ph0418s14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Prostanoids, which include the prostaglandins (PGs) and thromboxanes (TXs), interact with a specific family of G-protein coupled receptors, of which there are known to be five distinct types, DP, EP, FP, IP and TP, each particularly sensitive to one of the five natural prostanoids, PGD₂, PGE₂, PGF₂(, PGI₂ and TXA₂, respectively. Of these, it is known that the EP receptor comprises four well-characterized subtypes: EP₁, EP₂, EP₃ and EP₄. These receptor subtypes are widely distributed throughout mammals and other species, and show particularly high levels of expression in smooth muscle and blood platelets. Despite the fact that few of these preparations express a single receptor type/subtype in isolation, a range of useful smooth muscle and platelet assays for the various prostanoid receptors are available and are presented in this unit.
Collapse
Affiliation(s)
- J Chen
- Allergan, Irvine, California, USA
| | | | | | | | | |
Collapse
|
7
|
Pönicke K, Giessler C, Grapow M, Heinroth-Hoffmann I, Becker K, Osten B, Brodde OE. FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes. Br J Pharmacol 2000; 129:1723-31. [PMID: 10780979 PMCID: PMC1572001 DOI: 10.1038/sj.bjp.0703243] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The aim of this study was to characterize the receptor subtype involved in cardiac effects of prostanoids. For this purpose we determined in neonatal and adult rat cardiomyocytes effects of prostanoids on inositol phosphate (InsP)-formation (assessed as accumulation of total [(3)H]-InsP's in myo-[(3)H]-inositol pre-labelled cells) and on rate of protein synthesis (assessed as [(3)H]-phenylalanine incorporation), and on contractile force in left ventricular strips of the rat heart. For comparison, effects of prostanoids on InsP-formation and contractile force were determined in rat thoracic aorta, a classical TP-receptor containing tissue. Prostanoid increased InsP-formation and rate of protein synthesis in neonatal as well as adult rat cardiomyocytes; the order of potency was in neonatal (PGF(2alpha)>PGD(2)> or =PGE(2)> or =U 46619>PGE(1)) and adult (PGF(2alpha)>PGD(2)> or =PGE(2)>U 46619) rat cardiomyocytes well comparable. Moreover, in electrically driven left ventricular strips PGF(2alpha) caused positive inotropic effects (pD(2) 7.5) whereas U 46619 (up to 1 microM) was uneffective. In contrast, in rat thoracic aorta U 46619 was about 100 times more potent than PGF(2alpha) in increasing InsP-formation and contractile force. The TP-receptor antagonist SQ 29548 only weakly antagonized prostanoid-induced increases in rate of protein synthesis (pK(B) about 6) in rat cardiomyocytes but was very potent (pK(B) about 8-9) in antagonizing prostanoid-induced increases in InsP-formation and contractile force in rat aorta. We conclude that, in cardiomyocytes of neonatal and adult rats, the prostanoid-receptor mediating increases in InsP-formation and rate of protein synthesis is a FP-receptor. Moreover, stimulation of these cardiac FP-receptors can mediate increases in contractile force.
Collapse
Affiliation(s)
- K Pönicke
- Institute of Pharmacology and Toxicology, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 4, D-06097 Halle (Saale), Germany
| | - C Giessler
- Institute of Pharmacology and Toxicology, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 4, D-06097 Halle (Saale), Germany
| | - M Grapow
- Institute of Pharmacology and Toxicology, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 4, D-06097 Halle (Saale), Germany
| | - I Heinroth-Hoffmann
- Institute of Pharmacology and Toxicology, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 4, D-06097 Halle (Saale), Germany
| | - K Becker
- Institute of Pharmacology and Toxicology, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 4, D-06097 Halle (Saale), Germany
| | - B Osten
- Department of Nephrology, Ernst Grube Str. 40, D-06120 Halle (Saale), Germany
| | - O-E Brodde
- Institute of Pharmacology and Toxicology, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 4, D-06097 Halle (Saale), Germany
- Author for correspondence:
| |
Collapse
|
8
|
He GW, Yang CQ. Inhibition of vasoconstriction by the thromboxane A2 antagonist GR32191B in the human radial artery. Br J Clin Pharmacol 1999; 48:207-15. [PMID: 10417498 PMCID: PMC2014295 DOI: 10.1046/j.1365-2125.1999.00985.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/1998] [Accepted: 04/04/1999] [Indexed: 11/20/2022] Open
Abstract
AIMS The newly revived coronary bypass graft, the radial artery (RA), is more spastic than the internal mammary artery. Thromboxane A2 is a potent vasoconstrictor for arterial grafts. This study was therefore designed to determine whether the specific thromboxane A2 (TP) receptor antagonist, GR32191B, is effective in inhibition of prostanoid or nonprostanoid receptors in the RA. METHODS The effect of GR32191B was studied in human RA segments, taken from coronary bypass patients, in organ chambers. Two effects of GR32191B were tested: (1) the relaxation induced by GR32191B in the RA precontracted with the TP receptor agonists U46619 and PGF2alpha or nonprostanoid vasoconstrictors (noradrenaline [NA], angiotensin II [AII], and K+ ) and (2) the inhibitory effect of GR32191B on TP receptor agonists and nonprostanoid vasoconstrictors. RESULTS In U46619 (10 nm, n=7) and PGF2alpha (1 microm, n=7) precontracted RA, GR32191B induced 100% relaxation (10-100 microm ) but not after precontraction with nonprostanoid stimuli (5.8% for K+, 25 mm, n=6, 24.4% for NA, 3 microm, n=8, and 53.2% for AII, 3 nm, n=5) (P<0.001). Treatment with GR32191B (30 nm ) significantly depressed the contraction with U46619 (from 160.1+/-11.0% to 116.8+/-13.1%, P<0. 05) or PGF2alpha (from 91.3+/-12.3% to 42.2+/-9.2%, P<0.01). The contraction was further abolished by 3 microm GR32191B. However, GR32191B at 3 microm did not significantly inhibit the contraction induced by either NA, AII, or K+. CONCLUSIONS GR32191B is a highly potent and specific TP receptor antagonist for the human RA. It may be particularly useful in inhibiting TXA2-mediated vasoconstriction and therefore in reducing the complications related to vasospasm in this graft.
Collapse
Affiliation(s)
- G W He
- Cardiovascular Research Laboratory and Division of Cardiothoracic Surgery, Grantham Hospital, Department of Surgery and the Institute of Cardiovascular Science and Medicine, University of Hong Kong, Hong Kong
| | | |
Collapse
|
9
|
Kan WM, Yek YL. Synthesis of novel 7-oxabicyclo[2.2.1]-heptane thromboxane A2 derivatives containing substitution on positions one and two. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 1997; 407:497-501. [PMID: 9321997 DOI: 10.1007/978-1-4899-1813-0_74] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- W M Kan
- Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C
| | | |
Collapse
|
10
|
Jones RL, Qian YM, Wise H, Wong HN, Lam WL, Chan HW, Yim AP, Ho JK. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol 1997; 29:525-35. [PMID: 9156364 DOI: 10.1097/00005344-199704000-00015] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The specific prostacyclin (IP) receptor agonist cicaprost relaxed human pulmonary artery preparations precontracted with phenylephrine [50% inhibitory concentration (IC50) approximately 0.6 nM], U-46619 (IC50 approximately 0.9 nM), and K+ (approximately 40% maximal relaxation); endothelium removal had little effect on relaxant activity. Ranking of relaxant potencies for prostacyclin and five of its analogs was 17 alpha, 20-dimethyl-delta 6,6a-6a-carba PGI1 (TEI-9063) > or = cicaprost > iloprost > prostacyclin > taprostene > benzodioxane prostacyclin > 15-deoxy-16 alpha-hydroxy-16 beta,20-dimethyl-delta 6,6a-6a-carba PGI1 (TEI-3356). The potency of the isocarbacyclin TEI-3356 may have been under-estimated because of its contractile (EP3 receptor agonist) activity. The potency ranking of four nonprostanoid prostacyclin mimetics was 3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy] acetic acid (BMY 45778; IC50 approximately 2.5 nM) > > 2-[3-[2-(4, 5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid (BMY 42393) > octimibate > CU 23 (a novel diphenylindole). From IP receptor binding affinities obtained on human platelet membranes, it is suggested that the slightly shallower log concentration-response curves for BMY 45778, BMY 42393, and CU 23 may reflect the near-maximal receptor occupancy required for complete relaxation. A fifth nonprostanoid, CU 602, had much shallower log concentration-response curves than cicaprost against phenylephrine tone but not against U-46619 tone; this may indicate IP receptor partial agonism coupled with TP receptor antagonism. The relaxant actions of the nonprostanoid mimetics were more persistent than those of the prostacyclin analogs on washout of the organ bath; by the inhalation route, this type of compound may be retained within pulmonary tissue and thus afford greater pulmonary/systemic selectivity than currently used pulmonary vasodilators.
Collapse
Affiliation(s)
- R L Jones
- Department of Pharmacology, Chinese University of Hong Kong, Shatin, Hong Kong
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Krauss AH, Woodward DF, Gibson LL, Protzman CE, Williams LS, Burk RM, Gac TS, Roof MB, Abbas F, Marshall K, Senior J. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br J Pharmacol 1996; 117:1171-80. [PMID: 8882612 PMCID: PMC1909759 DOI: 10.1111/j.1476-5381.1996.tb16712.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
1. The pharmacological activity of a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha (PGF2 alpha) was investigated in various isolated smooth muscle preparations possessing different prostanoid receptor subtypes as well as in human platelets. Since subdivision of thromboxane (TP-) receptors into vascular/smooth muscle and platelet subtypes is a controversial subject, our studies included a human smooth muscle preparation (myometrium) in addition to the widely used rat aorta and human platelets as TP-receptor preparations. 2. Two members of that series, AGN191976 and AGN192093 were found to be highly potent and selective thromboxane-mimetics. AGN191976 and AGN192093 contracted isolated tissues of the rat thoracic aorta with EC50 values of 0.32 +/- 0.08 and 1.30 +/- 0.53 nM, respectively. Both agonists were at least 10 times more potent than the benchmark TP-agonist, U-46619, in this preparation, whilst being at least 500 times less potent at other prostanoid receptors (DP, EP1, EP3, FP, IP) in vitro. 3. In human myometrial strips from pregnant and non-pregnant donors, both AGN191976 and AGN192093 were potent contractile agonists. The rank order of potency in myometrium of AGN191976 > AGN192093 > U-46619 correlated well with that in the rat aorta. In human platelet-rich plasma (PRP), however, AGN191976 had potent proaggregatory activity (EC50 = 16.3 +/- 1.4 nM), which is a TP-receptor-mediated event, whereas AGN192093 was a much weaker agonist (EC50 = 37.9 +/- 2.0 microM). AGN192093 did not behave as an antagonist in the platelets, since it did not antagonize platelet aggregation induced by ADP, arachidonic acid, U-46619 or AGN191976. In human washed platelets, the activity profile of AGN191976 (EC50 = 4.15 +/- 0.52 nM) and AGN192093 (no aggregation up to 10 microM) was similar to that obtained in PRP. 4. The involvement of TP-receptors was verified with the potent TP-antagonist, SQ29548. SQ29548 (0.1 microM in myometrium; 1 microM in aorta; 1 microM and 10 microM in platelets) antagonized responses to U-46619, AGN191976 and AGN192093 as expected. 5. In conclusion, AGN191976 and AGN192093, both 9,11-cyclic carbonate derivatives of PGF2 alpha, were found to be highly potent and selective thromboxane-mimetics in rat vascular and human myometrial smooth muscle. However, only AGN 191976 was a potent agonist at TP-receptors in human platelets. The differential activity of AGN192093 on TP-receptor-mediated events in platelets and smooth muscle provides further evidence for a subdivision of TP-receptors. AGN192093 appears to be a useful tool for the pharmacological distinction of TP-receptor subtypes.
Collapse
MESH Headings
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
- Animals
- Blood Platelets/drug effects
- Blood Platelets/metabolism
- Bridged Bicyclo Compounds, Heterocyclic
- Dinoprost/pharmacology
- Dose-Response Relationship, Drug
- Fatty Acids, Unsaturated
- Humans
- Hydrazines/pharmacology
- In Vitro Techniques
- Muscle Contraction
- Muscle, Smooth/drug effects
- Muscle, Smooth/metabolism
- Platelet Aggregation
- Prostaglandin Endoperoxides, Synthetic/pharmacology
- Prostaglandins F, Synthetic/pharmacology
- Receptors, Thromboxane/drug effects
- Thromboxane A2/analogs & derivatives
- Thromboxane A2/pharmacology
- Vasoconstrictor Agents/pharmacology
Collapse
Affiliation(s)
- A H Krauss
- Department of Biological Sciences, Allergan, Inc., Irvine, CA 92713-9534, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Joachim KD, Klar U, Pletsch A, Rehwinkel H, Skuballa W. Novel prostanoid thromboxane A2 agonists. PROSTAGLANDINS 1995; 50:57-63. [PMID: 8588073 DOI: 10.1016/0090-6980(95)00048-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The chemistry and biology of novel TXA2(TP)-receptor agonists based on the prostanoid skeleton is described and structure-activity-relationships are discussed. One compound,(5Z,13E), (9R,15R)-9-fluoro-15-hydroxy-16-phenoxy-17,18,19,20-tetranor- 5,13-prostadienoic acid (33), was identified which is 10 times more potent than the standard TP-receptor against U 46619.
Collapse
Affiliation(s)
- K D Joachim
- Research Laboratories of Schering AG, Berlin, Germany
| | | | | | | | | |
Collapse
|
13
|
Abstract
1. The aim of this review is to establish what is known about the thromboxane (TP) receptor, and to identify where future research is headed. In addition, the impact of the recent advances at the molecular level on resolving pharmacological controversies, such as possible subtypes of the TP receptor, is discussed and what molecular information is known about the TP receptor presented. 2. The clinical status of TP receptor antagonists is considered particularly in relation to the potential role of epi prostaglandins. 3. Basic information about TP agonists, antagonists and signal transduction pathways is also given.
Collapse
Affiliation(s)
- R A Armstrong
- University of Edinburgh, Department of Pharmacology, Scotland
| | | |
Collapse
|
14
|
Tymkewycz PM, Jones RL, Wilson NH, Marr CG. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements. Br J Pharmacol 1995; 102:607-14. [PMID: 1364826 PMCID: PMC1917959 DOI: 10.1111/j.1476-5381.1991.tb12220.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
1. Thromboxane A2 (TP-) receptors in human, rat and rabbit platelets and in smooth muscle of guinea-pig trachea, rat aorta and rabbit aorta have been characterized by measurement of the potencies of agonists and antagonists having considerable variations in chemical structure. 2. On each washed platelet system, eight prostanoids induced maximal irreversible aggregation (full agonists) and the potency ranking was EP 171 > STA2 > 9,11-azo PGH2 > 9,11-endoxy-10a-homo PGH2 > U-46619 (standard) > PGH2 = 16-p-fluorophenoxy-omega-tetranor PGF2 alpha > 16,16-dimethyl PGF2 alpha. Correlations between the three platelet preparations for both absolute and relative potencies were good. On human platelets, STA2, at concentrations above that required for maximum aggregation, exerted an inhibitory effect which was independent of its interaction with the TP-receptor. 3. Five prostanoids, EP 109, EP 167, EP 204, PTA2 and 16,20-methano PTA2, exhibited partial agonist activity on the platelet and smooth muscle preparations. There was good agreement between absolute potencies on the six preparations; on platelets potency was assessed from shape change measurements, since aggregation, when present, always showed a very shallow concentration-response relationship. The magnitude of the maximum response induced by each compound decreased in the order listed above, to the extent that 16,20-methano PTA2 could be treated as a pure antagonist. 4. With U-46619 as agonist, the pA2 values of seven antagonists were found to be very similar on human and rat platelets. The potency ranking was EP 169 > AH 23848 > EP 092 > ONO 11120 > EP 115 = 16,20-methano PTA2 > BM 13177. There was a similar trend on rabbit platelets but pA2 values were 1.0-1.5 log units smaller; the exception was BM 13177 which had similar affinities. The antagonism produced by EP 169 and AH 23848 was surmountable on rabbit platelets but not on human and rat platelets. 5. None of the antagonists was highly potent on the rabbit aorta (pA2 values < 7.5 by Schild analysis). Affinities on the guinea-pig trachea and the rat aorta were higher and in the same range as those obtained for human and rat platelets. However the correlations of pA2 values between any pair of smooth muscle preparations and between any pair of platelet/smooth muscle preparations were either weak or not significant(P > 0.05). 6. The excellent agreement for both full and partial agonist potencies between the six preparations provides no evidence for TP-receptor subtypes and further suggests that the agonist recognition sites of the TP-receptors could be very similar, if not identical, in nature. In contrast, the different antagonist affinities found in this and other published studies indicate heterogeneity of TP-receptors. However, classification into TP,-, TP2-receptors, etc. on the basis of the limited antagonist data available does not appear appropriate at this time.
Collapse
|
15
|
Abstract
Many vasoconstrictor substances have been demonstrated as being vasodilators through the mechanism of endothelium-derived relaxing factor (EDRF) release. The authors have hypothesized that all naturally secreted vasoconstrictor substances may potentially be vasodilators as well in order to maintain an adequate physiological vascular tone. To test this hypothesis, they studied the effect of thromboxane A2--a naturally secreted vasoconstrictor substance released from platelets, which has not been demonstrated as an EDRF stimulus, using its stable analog U46619 in the porcine coronary artery (CA). The results have shown that U46619 is a stimulus for EDRF biosynthesis/release. This effect may be blocked by the specific inhibitor of EDRF biosynthesis/release NG-nitro-L-arginine (L-NNA). Therefore, this study supports the aforementioned hypothesis. The authors suggest that naturally secreted vasoconstrictor substances may be more accurately termed "vasoactivator" substances. These vasoactivators, according to the balance between their constrictive or relaxing effects, may be classified as (1) Type I: vasoconstriction-predominant type such as acetylcholine (ACh), and U46619 in porcine which mainly cause contraction in endothelium-intact arteries; (2) Type II: balanced type such as norepinephrine (NE) and 5-hydroxytryptamine (5-HT) in porcine CA, which cause little contraction in endothelium-intact arteries but cause a great contraction when the endothelium is denuded. Usually, the receptor subtypes located in the endothelium and smooth muscle stimulated by any one of these vasoactivator substances are different. All these characteristics of vasoconstrictor substances may play an important role in maintaining an adequate vascular tone.
Collapse
Affiliation(s)
- G W He
- Hospital For Sick Children, Toronto, Canada
| | | |
Collapse
|
16
|
Armstrong RA, Humphrey PP, Lumley P. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets. Br J Pharmacol 1993; 110:539-47. [PMID: 8242228 PMCID: PMC2175933 DOI: 10.1111/j.1476-5381.1993.tb13844.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
1. The interaction of the specific thromboxane (TP-) receptor blocking drug, [3H]-GR32191 with human intact platelets and platelet membranes has been investigated in vitro. 2. On intact platelets, association of specific [3H]-GR32191 binding at 37 degrees C was biphasic, with an initial rapid component and a slower secondary phase. Dissociation experiments indicated displacement from two sites with t1/2 values of 8.1 and 65.6 minutes. Kd values derived from the kinetic rate constants for the rapid onset/offset and slow onset/offset phases were 0.4 and 0.5 nM respectively. 3. Competition binding of [3H]-GR32191 and GR32191 on intact platelets gave an IC50 of 2.3 nM. Scatchard analysis indicated a single class of binding site with a Kd of 2.2 nM. Further analysis of the data yielded a Hill slope of -1.0 again indicating an interaction at a single binding site. Saturation binding experiments gave a similar estimate of the Kd value for [3H]-GR32191 to that obtained from competition binding experiments. A possible explanation for the biphasic interaction of the GR32191 in intact platelets may lie in restriction of its access to and egress from a population of TP-receptors. 4. In platelet membranes at 37 degrees C, specific [3H]-GR32191 binding was complete within 5 min with a calculated association rate constant of 3.2 x 10(8) M-1 min-1. Dissociation of [3H]-GR32191 was relatively slow, with measurable specific binding persisting for > 40 min. Analysis of these data yielded a t1/2 of 17.7 min and a dissociation rate constant of 0.04 min-1 and indicated dissociation from a single site. The ti for dissociation appeared to be related to the contact time of platelet membranes with [3H]-GR32191.Derivation of a Kd from the kinetic rate constants gave a value of 0.13 nM.5. Competition binding of [3H]-GR32191 and GR32191 to platelet membranes gave an IC50 value of 3.5 nM. Scatchard analysis of these data indicated a single binding site with a Kd of 2.1 nM. Saturation binding experiments with [3H]-GR32191 yielded similar IC50 and Kd values to those from competition experiments.6. In further competition binding experiments, the TP-receptor agonists U-46619, STA2, EP171 and 9,1 1-azo PGH2 and antagonists SQ29,548, BM 13.177 and EP092 all competed with specific [3H]-GR32191 binding on intact platelets and, where determined, on platelet membranes. All compounds fully displaced specific [3H]-GR32191 binding. However, where tested, the ICso values for a particular compound were always greater when [3H]-GR32191 was the radioligand than when [3H]-SQ29,548 was used. At the concentrations used in these studies (2 and 5 nM respectively), platelets appeared to bind approximately twice as much [3H]-GR32191 as [3H]-SQ29,548.7. In conclusion, the interaction of [3H]-GR32191 with human intact platelets was complex but the data were consistent with an action at a single class of binding site; from competition experiments this appears to be the functional TP-receptor. The interaction of the drug with this binding site is, however,characterized by a slow dissociation. This characteristic was confirmed in studies with platelet membranes and does not therefore appear to be an artefact of diffusion. Estimates of the Kd of the drug differed depending on the method of determination. Because of the slow dissociation of [3H]-GR32191,those relying upon equilibrium of the radioligand with competing agent may be unreliable. The rate of dissociation also appeared to be related to the contact time of drug with receptor. An explanation for this phenomenon may lie in the ability of GR32191 to induce a change in the conformational state or location of the human platelet TP-receptor.
Collapse
Affiliation(s)
- R A Armstrong
- Department of Pharmacology, University of Edinburgh Medical School
| | | | | |
Collapse
|
17
|
Muir G, Jones RL, Will SG, Winwick T, Peesapati V, Wilson NH, Griffiths N, Nicholson WV, Taylor P, Sawyer L, Blake AJ. Thromboxane receptor active analogues based on the 6-oxabicyclo[3.2.1]octane ring system. Eur J Med Chem 1993. [DOI: 10.1016/0223-5234(93)90092-s] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Lawrence RA, Jones RL. Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Br J Pharmacol 1992; 105:817-24. [PMID: 1324050 PMCID: PMC1908720 DOI: 10.1111/j.1476-5381.1992.tb09063.x] [Citation(s) in RCA: 73] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
1. Prostaglandin E2 (PGE2) relaxes circular smooth muscle of the rabbit isolated jugular vein at very low concentrations (mean pIC50 against histamine-induced contraction = 9.34). This effect is not blocked by the EP1-receptor antagonist, AH 6809 (2 microM). 2. From a group of prostaglandin E analogues examined, 16,16-dimethyl PGE2, misoprostol, 11-deoxy PGE2-1-alcohol and 11-deoxy PGE1 were highly potent relaxant agents, whereas 17-phenyl-omega-trinor PGE2, MB 28767 and butaprost had low potency and sulprostone and oxoprostol were virtually inactive. 3. Comparison of the jugular vein data with published data for inhibitory agonist potencies on the cat trachea (EP2 preparation) and the field-stimulated guinea-pig vas deferens (EP3) indicates that the EP-receptor in the rabbit jugular vein is closest to the EP2 subtype. However, the correlation is not entirely convincing. For example, butaprost, 16,16-dimethyl PGE2 and 11-deoxy PGE1 are of similar potency on the cat trachea, whereas butaprost is about 300 times less potent than the other two analogues on the jugular vein. The existence of more than one EP2-receptor appears possible. 4. It was felt that the activity of butaprost required further investigation in view of the claim that it is a specific EP2-receptor agonist. We have shown that butaprost has very low inhibitory activity on the guinea-pig vas deferens, a very sensitive EP3-receptor containing preparation. However, on the chick ileum, the original EP3 preparation, butaprost showed potent contractile activity (pEC25 approximately 8.0).In addition, its maximum response was lower than that of PGE2; lower maxima were also found for sulprostone, MB 28767 and oxoprostol, but not for ICI 80205, 16,16-dimethyl PGE2 and 17-phenyl-omega-trinor PGE2. The maximal response to a combination of either sulprostone and butaprost or sulprostone and PGE2 was similar to that achieved by PGE2 alone. Analysis of the interaction between sulprostone and PGE2 appears to exclude a partial agonist action for sulprostone. Furthermore neither sulprostone nor butaprost appear to have inhibitory activity on the ileum. AH 6809 at 2 pM produced only a small shift of the PGE2 log concentration-response curve.5. It is likely that contraction of the longitudinal smooth muscle of the chick ileum is mediated by (at least) two EP-receptor subtypes; activation of only one receptor system does not induce the maximum response (i.e. the acetylcholine maximum) of the preparation. One receptor could be an EP3 subtype, at which sulprostone exerts a selective agonist action. The other receptor is unlikely to be an EP, subtype, because of the high agonist potency of butaprost, the low agonist potency of iloprost, and the low antagonist potency of AH 6809. An alternative hypothesis is that the chick ileum contains a novel EP-receptor subtype in addition to an EP3-receptor.
Collapse
Affiliation(s)
- R A Lawrence
- Department of Pharmacology, University of Edinburgh
| | | |
Collapse
|
19
|
Affiliation(s)
- S E Hall
- Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08540
| |
Collapse
|
20
|
Templeton AG, McGrath JC, Whittle MJ. The role of endogenous thromboxane in contractions to U46619, oxygen, 5-HT and 5-CT in the human isolated umbilical artery. Br J Pharmacol 1991; 103:1079-84. [PMID: 1878747 PMCID: PMC1908072 DOI: 10.1111/j.1476-5381.1991.tb12303.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
1. The effects of selective thromboxane antagonists and a thromboxane synthase inhibitor on the contraction to 9,11-dideoxy-11 alpha,9 alpha-epoxymethano-prostaglandin F2 alpha (U46619) and oxygen in the human umbilical artery (HUA) were examined. The effect of the antagonists on contractions to both 5-hydroxytryptamine (5-HT) and 5-carboxamidotryptamine (5-CT) were also examined. 2. U46619 (0.3 nM-10 microM) contracted the HUA. This contraction was antagonized by two selective thromboxane receptor antagonists EP092 (10 nM-1 microM) and GR32191B (10 nM-1 microM). The contraction was not affected by the selective thromboxane synthase inhibitor, dazoxiben (10 nM-1 microM). 3. When the oxygen tension was increased from 16 mmHg to 120 mmHg, the HUA transiently contracted. Both thromboxane antagonists inhibited this contraction in a concentration-dependent manner with 1 microM almost completely abolishing the response (the oxygen-induced contraction of the control preparation normally increases with a second exposure to 120 mmHg oxygen). 4. In low (16 mmHg) oxygen, responses to both 5-HT and 5-CT were unaffected by both thromboxane receptor antagonists at concentrations up to 1 microM. In high oxygen (120 mmHg) responses to both 5-HT and 5-CT were biphasic in nature, with an additional initial high sensitivity phase, which was abolished by a cyclo-oxygenase inhibitor. In high oxygen, EP092 and GR32191B blocked this initial phase in a concentration-dependent manner, returning sensitivity to 5-HT and 5-CT to that seen in low oxygen. 5. The thromboxane synthase inhibitor, dazoxiben, at concentrations greater than 10 nm inhibited the contraction to 120 mmHg oxygen and at 1 microM, dazoxiben almost abolished the response. In low oxygen, the response to 5-HT was unaffected by dazoxiben at concentrations up to 10 microM. In high oxygen, the initial phase of the contraction to 5-HT was inhibited by concentrations greater than 10 nm, with no effect on the maximum response. 6. The results show that thromboxane receptor antagonism or blockade of thromboxane synthesis selectively attenuates oxygen-induced contractions and those responses to 5-HT and 5-CT which are dependent on high oxygen for their expression. This suggests that the contractions caused by high oxygen tension, and the enhancement of the contractile effects of low concentrations of 5-HT and 5-CT in the presence of high oxygen tension are mediated by endogenously released thromboxane A2.
Collapse
|
21
|
Affiliation(s)
- W G Nayler
- Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia
| |
Collapse
|
22
|
POSTER COMMUNICATIONS. Br J Pharmacol 1989. [DOI: 10.1111/j.1476-5381.1989.tb17393.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|